WO2011000566A3 - Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections - Google Patents

Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections Download PDF

Info

Publication number
WO2011000566A3
WO2011000566A3 PCT/EP2010/003967 EP2010003967W WO2011000566A3 WO 2011000566 A3 WO2011000566 A3 WO 2011000566A3 EP 2010003967 W EP2010003967 W EP 2010003967W WO 2011000566 A3 WO2011000566 A3 WO 2011000566A3
Authority
WO
WIPO (PCT)
Prior art keywords
negative
pharmaceutical compositions
compounds
treatment
virus infections
Prior art date
Application number
PCT/EP2010/003967
Other languages
French (fr)
Other versions
WO2011000566A2 (en
Inventor
Dirk Classen-Houben
Oliver Szolar
Peter Sehr
Bernd Wendt
Delphine Gulligay
Stephen Cusack
Joe Lewis
Original Assignee
Savira Pharmaceuticals Gmbh
European Molecular Biology Laboratory (Embl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals Gmbh, European Molecular Biology Laboratory (Embl) filed Critical Savira Pharmaceuticals Gmbh
Publication of WO2011000566A2 publication Critical patent/WO2011000566A2/en
Publication of WO2011000566A3 publication Critical patent/WO2011000566A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to novel compounds and pharmaceutical compositions and the use thereof for the manufacture of a medicament for treating, ameliorating, or preventing disease conditions caused by a viral infection with negative-sense ssRNA viruses.
PCT/EP2010/003967 2009-06-30 2010-06-30 Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections WO2011000566A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22190209P 2009-06-30 2009-06-30
US61/221,902 2009-06-30
US25111809P 2009-10-13 2009-10-13
US61/251,118 2009-10-13

Publications (2)

Publication Number Publication Date
WO2011000566A2 WO2011000566A2 (en) 2011-01-06
WO2011000566A3 true WO2011000566A3 (en) 2011-05-26

Family

ID=43234276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/003967 WO2011000566A2 (en) 2009-06-30 2010-06-30 Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Country Status (1)

Country Link
WO (1) WO2011000566A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829007B2 (en) 2009-06-17 2014-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008374A2 (en) 2010-10-05 2016-06-14 Purdue Pharma Lp quinazoline compound as sodium channel blocker
MX350993B (en) * 2010-10-28 2017-09-27 Procter & Gamble Personal care compositions comprising a pyrithione and an iron chelator.
US10663461B2 (en) 2010-11-30 2020-05-26 Ge Healthcare Bio-Sciences Ab Screening method
JP2013545816A (en) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド Influenza virus replication inhibitor
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102600A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US9434745B2 (en) 2012-05-23 2016-09-06 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
BR112014029006A2 (en) 2012-05-23 2017-06-27 European Molecular Biology Laboratory 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives that are useful in treating, ameliorating or preventing a viral disease.
US20150164910A1 (en) * 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
WO2014023691A1 (en) 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014108406A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150103034A (en) 2013-01-08 2015-09-09 사피라 파르마슈티칼즈 게엠베하 Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150103672A (en) 2013-01-08 2015-09-11 사피라 파르마슈티칼즈 게엠베하 Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2015054838A (en) * 2013-09-12 2015-03-23 興和株式会社 Medicament for reduction of blood ldl cholesterol
WO2015073476A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
HUE052178T2 (en) 2013-11-13 2021-04-28 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
CN107074880A (en) 2014-07-07 2017-08-18 萨维拉制药有限公司 The diketone of dihydro pyrido pyrazine 1,8 and their purposes in treating, ameliorating or preventing virus disease
JP6434614B2 (en) * 2014-08-22 2018-12-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Indazole
CN104496947A (en) * 2014-12-02 2015-04-08 中国科学院昆明植物研究所 Ganoderma lucidum compounds and medicine composition thereof, as well as preparation method and application of compounds
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
MA42422A (en) 2015-05-13 2018-05-23 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US10696687B2 (en) * 2015-08-20 2020-06-30 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
US20170081324A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20170081323A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
WO2018001948A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
EP3548034A4 (en) * 2016-12-05 2020-07-08 Microbiotix, Inc. Broad-spectrum inhibitors of filoviruses
DE102020125641A1 (en) * 2020-09-25 2022-03-31 Creative Therapeutics Gmbh Active substances and medicines for the therapy of viral diseases, in particular corona infections, in particular COVID-19
CN115872995A (en) * 2022-12-27 2023-03-31 上海凌凯医药科技有限公司 Preparation method of pyrazolopyridine compound and carboxylic acid derivative

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2006083271A2 (en) * 2004-05-18 2006-08-10 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006110762A2 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceutical compositions for and methods of inhibiting hcv replication
US20070010455A1 (en) * 2005-07-11 2007-01-11 Piyasena Hewawasam Hepatitis C virus inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008082484A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2006083271A2 (en) * 2004-05-18 2006-08-10 Achillion Pharmaceuticals, Inc. Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006110762A2 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceutical compositions for and methods of inhibiting hcv replication
US20070010455A1 (en) * 2005-07-11 2007-01-11 Piyasena Hewawasam Hepatitis C virus inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
WO2008082484A1 (en) * 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATTABY, FAWZY ET AL: "Synthesis, Reactions, and Antiviral Activity of 1-(1H-Pyrazolo[3,4-b]pyridin-5-yl)ethanone and Pyrido[2',3':3,4]pyrazolo[5,1-c][1,2,4]triazine Derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 181, no. 5, 2010, pages 1087 - 1102, XP008130501 *
DORSEY, BRUCE D. ET AL: "Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 18, 2000, pages 3386 - 3399, XP002614402 *
LACOVA, MARGITA ET AL: "3-formylchromones IV. The rearrangement of 3-formylchromone enamines as a simple, facile route to novel pyrazolo[3,4-b]pyridines and the synthetic utility of the latter", MOLECULES, vol. 10, no. 7, 2005, pages 809 - 821, XP002614406 *
RYABUKHIN, SERGEY V. ET AL: "Chlorotrimethylsilane-mediated synthesis of functionalized fused pyridines: reaction of 3-formylchromones with electron-rich aminoheterocycles", SYNTHESIS, vol. 12, 2007, pages 1861 - 1871, XP002614405 *
SANGHVI, YOGESH S. ET AL: "Synthesis and biological evaluation of certain C-4 substituted pyrazolo[3,4-b]pyridine nucleosides", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 5, 1989, pages 945 - 951, XP002614401 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829007B2 (en) 2009-06-17 2014-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication

Also Published As

Publication number Publication date
WO2011000566A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
EA201301320A1 (en) 4-aryl-n-phenyl-1,3,5-triazine-2-amines, which contain a sulphoxyimin group
EA201301158A1 (en) ANTI-VIRUS COMPOUNDS
PH12015500355A1 (en) Compounds for the treatment of paramoxyvirus viral infections
MY182771A (en) Viral replication inhibitors
BRPI1014322A2 (en) Method for treating infection, and for interrupting or preventing the production of infectious viral particles, combination, and pharmaceutical composition.
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
MY158757A (en) Viral inhibitor composition for in vivo threpeutic use
WO2011158039A8 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
EA201300135A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF INFECTIOUS DISEASES
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
JO3281B1 (en) Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections
MY194294A (en) Novel viral replication inhibitors
WO2015039010A3 (en) Deoxynojirimycin derivatives and methods of their using
SG179082A1 (en) Method for the preparation of an influenza virus
WO2011076367A3 (en) Synergistic antiviral composition and use thereof
EA201170605A1 (en) CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE
EA201491969A1 (en) IMMUNOGENIC COMPOUNDS INCLUDING HIV PEPTIDE GP41, ASSOCIATED WITH CRM197 CARRIER MEDICINE
TW201129572A (en) Compounds for treating respiratory syncytial virus infections
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
EA201590124A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF PNEUMATIC VIRUS INFECTION AND RELATED DISEASES
WO2010138419A3 (en) Materials and methods for treating viral infections

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10729816

Country of ref document: EP

Kind code of ref document: A2